🚀 VC round data is live in beta, check it out!
Avalo Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Avalo Therapeutics and similar public comparables like SIGA Technologies, Celon Pharma, Northwest Biotherapeutics, Organogenesis and more.
Avalo Therapeutics Overview
About Avalo Therapeutics
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Founded
2011
HQ
Employees
23
Website
Sectors
Financials (LTM)
EV
$213M
Avalo Therapeutics Financials
Avalo Therapeutics reported last 12-month revenue of $43K.
In the same LTM period, Avalo Therapeutics generated $43K in gross profit and had net loss of ($77M).
Revenue (LTM)
Avalo Therapeutics P&L
In the most recent fiscal year, Avalo Therapeutics reported revenue of $59K and EBITDA of ($73M).
Avalo Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $43K | XXX | $59K | XXX | XXX | XXX |
| Gross Profit | $43K | XXX | $59K | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($73M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (123019%) | XXX | XXX | XXX |
| EBIT Margin | (173745%) | XXX | (123602%) | XXX | XXX | XXX |
| Net Profit | ($77M) | XXX | ($78M) | XXX | XXX | XXX |
| Net Margin | (179982%) | XXX | (132642%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Avalo Therapeutics Stock Performance
Avalo Therapeutics has current market cap of $311M, and enterprise value of $213M.
Market Cap Evolution
Avalo Therapeutics' stock price is $13.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $213M | $311M | -4.1% | XXX | XXX | XXX | $-3.43 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAvalo Therapeutics Valuation Multiples
Avalo Therapeutics trades at 4999.4x EV/Revenue multiple, and (2.9x) EV/EBITDA.
EV / Revenue (LTM)
Avalo Therapeutics Financial Valuation Multiples
As of April 11, 2026, Avalo Therapeutics has market cap of $311M and EV of $213M.
Equity research analysts estimate Avalo Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Avalo Therapeutics has a P/E ratio of (4.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $311M | XXX | $311M | XXX | XXX | XXX |
| EV (current) | $213M | XXX | $213M | XXX | XXX | XXX |
| EV/Revenue | 4999.4x | XXX | 3616.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.9x) | XXX | XXX | XXX |
| EV/EBIT | (2.9x) | XXX | (2.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 4999.4x | XXX | 3616.0x | XXX | XXX | XXX |
| P/E | (4.1x) | XXX | (4.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Avalo Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Avalo Therapeutics Margins & Growth Rates
Avalo Therapeutics' revenue in the last 12 month declined by (100%).
Avalo Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $3.2M for the same period.
Avalo Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (100%) | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (123019%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 78% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 797% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 53776% | XXX | 38814% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 119689% | XXX | 84900% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 123702% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Avalo Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SIGA Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Celon Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Northwest Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Organogenesis | XXX | XXX | XXX | XXX | XXX | XXX |
| Ourofino | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Avalo Therapeutics M&A Activity
Avalo Therapeutics acquired XXX companies to date.
Last acquisition by Avalo Therapeutics was on XXXXXXXX, XXXXX. Avalo Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Avalo Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAvalo Therapeutics Investment Activity
Avalo Therapeutics invested in XXX companies to date.
Avalo Therapeutics made its latest investment on XXXXXXXX, XXXXX. Avalo Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Avalo Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Avalo Therapeutics
| When was Avalo Therapeutics founded? | Avalo Therapeutics was founded in 2011. |
| Where is Avalo Therapeutics headquartered? | Avalo Therapeutics is headquartered in United States. |
| How many employees does Avalo Therapeutics have? | As of today, Avalo Therapeutics has over 23 employees. |
| Who is the CEO of Avalo Therapeutics? | Avalo Therapeutics' CEO is Garry A. Neil. |
| Is Avalo Therapeutics publicly listed? | Yes, Avalo Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Avalo Therapeutics? | Avalo Therapeutics trades under AVTX ticker. |
| When did Avalo Therapeutics go public? | Avalo Therapeutics went public in 2015. |
| Who are competitors of Avalo Therapeutics? | Avalo Therapeutics main competitors are SIGA Technologies, Celon Pharma, Northwest Biotherapeutics, Organogenesis. |
| What is the current market cap of Avalo Therapeutics? | Avalo Therapeutics' current market cap is $311M. |
| What is the current revenue of Avalo Therapeutics? | Avalo Therapeutics' last 12 months revenue is $43K. |
| What is the current revenue growth of Avalo Therapeutics? | Avalo Therapeutics revenue growth (NTM/LTM) is (100%). |
| What is the current EV/Revenue multiple of Avalo Therapeutics? | Current revenue multiple of Avalo Therapeutics is 4999.4x. |
| Is Avalo Therapeutics profitable? | No, Avalo Therapeutics is not profitable. |
| What is the current net income of Avalo Therapeutics? | Avalo Therapeutics' last 12 months net income is ($77M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.